{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:16:44Z","timestamp":1790227004191,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Although adaptive immune responses against hepatitis C virus (HCV) infection have been studied in great detail, the role of innate immunity in protection against HCV infection and immune evasion is only partially understood. Interferon\u2010induced transmembrane proteins (IFITMs) are innate effector proteins restricting host cell entry of many enveloped viruses, including HCV. However, the clinical impact of IFITMs on HCV immune escape remains to be determined. Here, we show that IFITMs promote viral escape from the neutralizing antibody (nAb) response in clinical cohorts of HCV\u2010infected patients. Using pseudoparticles bearing HCV envelope proteins from acutely infected patients, we show that HCV variants isolated preseroconversion are more sensitive to the antiviral activity of IFITMs than variants from patients isolated during chronic infection postseroconversion. Furthermore, HCV variants escaping nAb responses during liver transplantation exhibited a significantly higher resistance to IFITMs than variants that were eliminated posttransplantation. Gain\u2010of\u2010function and mechanistic studies revealed that IFITMs markedly enhance the antiviral activity of nAbs and suggest a cooperative effect of human monoclonal antibodies and IFITMs for antibody\u2010mediated neutralization driving the selection pressure in viral evasion. Perturbation studies with the IFITM antagonist amphotericin B revealed that modulation of membrane properties by IFITM proteins is responsible for the IFITM\u2010mediated blockade of viral entry and enhancement of antibody\u2010mediated neutralization. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Our results indicate IFITM proteins as drivers of viral immune escape and antibody\u2010mediated HCV neutralization in acute and chronic HCV infection. These findings are of clinical relevance for the design of urgently needed HCV B\u2010cell vaccines and might help to increase the efficacy of future vaccine candidates.<\/jats:p>","DOI":"10.1002\/hep.30699","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T07:34:57Z","timestamp":1557214497000},"page":"1506-1520","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Interferon\u2010Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection"],"prefix":"10.1097","volume":"70","author":[{"given":"Florian","family":"Wrensch","sequence":"first","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1237-1936","authenticated-orcid":false,"given":"Ga\u00ebtan","family":"Ligat","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Heydmann","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Schuster","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam B.","family":"Zeisel","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"},{"name":"Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon (CRCL),Universit\u00e9 de Lyon (UCBL),Lyon,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pessaux","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"},{"name":"Institut Hospitalo\u2010Universitaire, P\u00f4le H\u00e9pato\u2010digestif,H\u00f4pitaux Universitaires de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Habersetzer","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"},{"name":"Institut Hospitalo\u2010Universitaire, P\u00f4le H\u00e9pato\u2010digestif,H\u00f4pitaux Universitaires de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas J.","family":"King","sequence":"additional","affiliation":[{"name":"School of Life Sciences,The University of Nottingham,Nottingham,United Kingdom"},{"name":"NIHR Nottingham BRC,Nottingham University Hospitals NHS Trust and the University of Nottingham,Nottingham,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Tarr","sequence":"additional","affiliation":[{"name":"School of Life Sciences,The University of Nottingham,Nottingham,United Kingdom"},{"name":"NIHR Nottingham BRC,Nottingham University Hospitals NHS Trust and the University of Nottingham,Nottingham,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan K.","family":"Ball","sequence":"additional","affiliation":[{"name":"School of Life Sciences,The University of Nottingham,Nottingham,United Kingdom"},{"name":"NIHR Nottingham BRC,Nottingham University Hospitals NHS Trust and the University of Nottingham,Nottingham,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Winkler","sequence":"additional","affiliation":[{"name":"Infection Biology Unit,German Primate Center\u2013Leibniz Institute for Primate Research,G\u00f6ttingen,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[{"name":"Infection Biology Unit,German Primate Center\u2013Leibniz Institute for Primate Research,G\u00f6ttingen,Germany"},{"name":"Faculty of Biology and Psychology,University of G\u00f6ttingen,G\u00f6ttingen,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen\u2010yong","family":"Keck","sequence":"additional","affiliation":[{"name":"Department of Pathology,Stanford University School of Medicine,Stanford,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.H.","family":"Foung","sequence":"additional","affiliation":[{"name":"Department of Pathology,Stanford University School of Medicine,Stanford,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[{"name":"Inserm, U1110,Institute for Viral and Liver Disease,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"},{"name":"Institut Hospitalo\u2010Universitaire, P\u00f4le H\u00e9pato\u2010digestif,H\u00f4pitaux Universitaires de Strasbourg,Strasbourg,France"},{"name":"Institut Universitaire de France,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"hep30699-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2014the arc of a medical triumph","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"hep30699-bib-0003-20241017","first-page":"S34","article-title":"A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep30699-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","article-title":"Treatment of hepatitis C in difficult\u2010to\u2010treat patients","volume":"12","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep30699-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment\u2010experienced patients with HCV\u2010cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20\u2010CUPIC)\u2014NCT01514890","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep30699-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep30699-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jir399","article-title":"Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross\u2010neutralize heterologous virus strains","volume":"204","year":"2011","journal-title":"J Infect Dis"},{"key":"hep30699-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","year":"2008","journal-title":"Nat Med"},{"key":"hep30699-bib-0009-20241017","first-page":"254ra129","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"hep30699-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp1802256","article-title":"Monoclonal antibodies for emerging infectious diseases\u2014borrowing from history","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"hep30699-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","year":"2011","journal-title":"Nature"},{"key":"hep30699-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1111\/j.1365-2893.2011.01452.x","article-title":"Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line","volume":"18","year":"2011","journal-title":"J Viral Hepat"},{"key":"hep30699-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep.26066","article-title":"IFITM1 is a tight junction protein that inhibits hepatitis C virus entry","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep30699-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"25946","DOI":"10.1074\/jbc.M115.657346","article-title":"The interferon\u2010induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry","volume":"290","year":"2015","journal-title":"J Biol Chem"},{"key":"hep30699-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-virology-031413-085537","article-title":"IFITM\u2010family proteins: the cell's first line of antiviral defense","volume":"1","year":"2014","journal-title":"Annu Rev Virol"},{"key":"hep30699-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"e1003124","DOI":"10.1371\/journal.ppat.1003124","article-title":"IFITM proteins restrict viral membrane hemifusion","volume":"9","year":"2013","journal-title":"PLoS Pathog"},{"key":"hep30699-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"e1004048","DOI":"10.1371\/journal.ppat.1004048","article-title":"IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus\u2010endosome hemifusion","volume":"10","year":"2014","journal-title":"PLoS Pathog"},{"key":"hep30699-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.celrep.2016.09.084","article-title":"Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes","volume":"17","year":"2016","journal-title":"Cell Rep"},{"key":"hep30699-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus\u2010neutralizing antibodies and viral clearance in a single\u2010source outbreak of hepatitis C","volume":"104","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep30699-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"key":"hep30699-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibody\u2010mediated neutralization influence hepatitis C virus reinfection in liver transplantation","volume":"207","year":"2010","journal-title":"J Exp Med"},{"key":"hep30699-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.gastro.2012.04.006","article-title":"Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies","volume":"143","year":"2012","journal-title":"Gastroenterology"},{"key":"hep30699-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.gastro.2015.09.014","article-title":"Apolipoprotein E mediates evasion from hepatitis C virus neutralizing antibodies","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep30699-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1053\/j.gastro.2008.07.018","article-title":"Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion","volume":"135","year":"2008","journal-title":"Gastroenterology"},{"key":"hep30699-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.23445","article-title":"Inhibition of hepatitis C virus infection by anti\u2010claudin\u20101 antibodies is mediated by neutralization of E2\u2010CD81\u2010claudin\u20101 associations","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep30699-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","year":"2005","journal-title":"J Virol"},{"key":"hep30699-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","year":"2000","journal-title":"J Virol"},{"key":"hep30699-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","year":"2008","journal-title":"J Virol"},{"key":"hep30699-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","year":"2012","journal-title":"PLoS Pathog"},{"key":"hep30699-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.3390\/v6093683","article-title":"IFITM proteins inhibit entry driven by the MERS\u2010coronavirus spike protein: evidence for cholesterol\u2010independent mechanisms","volume":"6","year":"2014","journal-title":"Viruses"},{"key":"hep30699-bib-0031-20241017","first-page":"3288","article-title":"A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance","volume":"90","year":"2015","journal-title":"J Virol"},{"key":"hep30699-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/hep.20542","article-title":"Characterization of host\u2010range and cell entry properties of the major genotypes and subtypes of hepatitis C virus","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep30699-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.87.24.9524","article-title":"Molecular cloning of the human hepatitis C virus genome from Japanese patients with non\u2010A, non\u2010B hepatitis","volume":"87","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep30699-bib-0034-20241017","first-page":"736","article-title":"Humanisation of a claudin\u20101\u2010specific monoclonal antibody for clinical prevention and cure of HCV infection without escape","volume":"67","year":"2018","journal-title":"Gut"},{"key":"hep30699-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1099\/jgv.0.000530","article-title":"Flexible and rapid construction of viral chimeras applied to hepatitis C virus","volume":"97","year":"2016","journal-title":"J Gen Virol"},{"key":"hep30699-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1039\/c1cp21386e","article-title":"Why BLUF photoreceptors with roseoflavin cofactors lose their biological functionality","volume":"13","year":"2011","journal-title":"Phys Chem Chem Phys"},{"key":"hep30699-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","year":"2005","journal-title":"Nat Med"},{"key":"hep30699-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chom.2010.12.002","article-title":"Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment","volume":"9","year":"2011","journal-title":"Cell Host Microbe"},{"key":"hep30699-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","volume":"103","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"hep30699-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"e1001258","DOI":"10.1371\/journal.ppat.1001258","article-title":"Distinct patterns of IFITM\u2010mediated restriction of filoviruses, SARS coronavirus, and influenza A virus","volume":"7","year":"2011","journal-title":"PLoS Pathog"},{"key":"hep30699-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.chom.2013.03.006","article-title":"The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry","volume":"13","year":"2013","journal-title":"Cell Host Microbe"},{"key":"hep30699-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"32184","DOI":"10.1074\/jbc.M113.514356","article-title":"Interferon\u2010induced transmembrane protein 3 is a type II transmembrane protein","volume":"288","year":"2013","journal-title":"J Biol Chem"},{"key":"hep30699-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.celrep.2013.10.033","article-title":"Amphotericin B increases influenza A virus infection by preventing IFITM3\u2010mediated restriction","volume":"5","year":"2013","journal-title":"Cell Rep"},{"key":"hep30699-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2014.06.035","article-title":"Innate and adaptive immune responses in HCV infections","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep30699-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/hep.26770","article-title":"Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep30699-bib-0046-20241017","first-page":"e00246","article-title":"pH optimum of hemagglutinin\u2010mediated membrane fusion determines sensitivity of influenza A viruses to the interferon\u2010induced antiviral state and IFITMs","volume":"91","year":"2017","journal-title":"J Virol"},{"key":"hep30699-bib-0047-20241017","first-page":"e01488","article-title":"Virion background and efficiency of virion incorporation determine susceptibility of simian immunodeficiency virus Env\u2010driven viral entry to inhibition by IFITM proteins","volume":"91","year":"2017","journal-title":"J Virol"},{"key":"hep30699-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1053\/j.gastro.2013.08.034","article-title":"Use of laser capture microdissection to map hepatitis C virus\u2010positive hepatocytes in human liver","volume":"145","year":"2013","journal-title":"Gastroenterology"},{"key":"hep30699-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cell.2017.11.018","article-title":"Intrinsic immunity shapes viral resistance of stem cells","volume":"172","year":"2018","journal-title":"Cell"},{"key":"hep30699-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.chom.2016.08.006","article-title":"Resistance of transmitted founder HIV\u20101 to IFITM\u2010mediated restriction","volume":"20","year":"2016","journal-title":"Cell Host Microbe"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30699","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:35:02Z","timestamp":1729211702000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30699","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"assertion":[{"value":"2018-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}